Tonix Pharmaceuticals (NASDAQ: TNXP) announced a second major managed Medicare agreement for TONMYA® (cyclobenzaprine HCl sublingual tablets), its flagship treatment for fibromyalgia in adults. The agreement, effective immediately, adds approximately 21 million Medicare lives, bringing total Medicare coverage to approximately 32 million lives. This represents 58% of the approximately 55 million Medicare lives in the United States. Combined with commercial and government payer coverage, TONMYA® now reaches approximately 166 million covered lives, or 53% of the total U.S. population of about 314 million.
The significance of this expanded coverage lies in its potential to accelerate patient access to the first new fibromyalgia treatment in more than 15 years. Fibromyalgia is a chronic condition affecting millions of Americans, often with limited effective options. By securing broader payer coverage, Tonix is positioning TONMYA® as a more readily available choice for patients and healthcare providers. The immediate effect of the agreement means that more Medicare beneficiaries will have access to the therapy without the delays often associated with prior authorization or formulary restrictions.
In addition to the payer expansion, Tonix has activated approximately 50 new sales representatives, bringing its total sales force to 150. This field force expansion is critical for driving awareness and adoption among physicians. The company has previously announced commercial payer agreements with two leading group purchasing organizations and one major managed Medicare agreement. TONMYA® is also covered by Medicaid in nearly all states, further solidifying its market reach. These commercial infrastructure investments reflect Tonix's commitment to maximizing the potential of its flagship product.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. Beyond TONMYA®, the company markets acute migraine products Zembrace® SymTouch® and Tosymra®. Tonix is also pursuing Phase 2 clinical trials to evaluate TONMYA® for major depressive disorder and acute stress disorder. Its CNS pipeline includes TNX-2900, which is Phase 2 ready for Prader-Willi syndrome, a rare disease. In immunology, Tonix is advancing TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for kidney transplant rejection prevention. These candidates remain investigational, with efficacy and safety not yet established.
The broader implications of this announcement extend beyond Tonix. It signals growing payer confidence in TONMYA® and underscores the commercial viability of novel CNS therapies. For investors, the expanded coverage and sales force may translate into increased revenue potential. For patients, it means improved access to a much-needed treatment option. As Tonix continues to execute its commercial strategy, the company is well-positioned to capture a significant share of the fibromyalgia market. The latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP.
InvestorWire, a specialized communications platform, distributed the original press release. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For full terms of use, see the disclaimer at https://www.InvestorWire.com/Disclaimer.
